Literature DB >> 20221410

Methods for optimizing statistical analyses in pharmacogenomics research.

Stephen D Turner1, Dana C Crawford, Marylyn D Ritchie.   

Abstract

Pharmacogenomics is a rapidly developing sector of human genetics research with arguably the highest potential for immediate benefit. There is a considerable body of evidence demonstrating that variability in drug-treatment response can be explained in part by genetic variation. Subsequently, much research has ensued and is ongoing to identify genetic variants associated with drug-response phenotypes. To reap the full benefits of the data we collect we must give careful consideration to the study population under investigation, the phenotype being examined and the statistical methodology used in data analysis. Here, we discuss principles of study design and optimizing statistical methods for pharmacogenomic studies when the outcome of interest is a continuous measure. We review traditional hypothesis testing procedures, as well as novel approaches that may be capable of accounting for more variance in a quantitative pharmacogenomic trait. We give examples of studies that have employed the analytical methodologies discussed here, as well as resources for acquiring software to run the analyses.

Entities:  

Year:  2009        PMID: 20221410      PMCID: PMC2835152          DOI: 10.1586/ecp.09.32

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  106 in total

1.  Genomic control for association studies.

Authors:  B Devlin; K Roeder
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

Review 2.  Pharmacogenetics in cancer treatment.

Authors:  R Nagasubramanian; F Innocenti; M J Ratain
Journal:  Annu Rev Med       Date:  2001-12-03       Impact factor: 13.739

Review 3.  Mapping complex disease loci in whole-genome association studies.

Authors:  Christopher S Carlson; Michael A Eberle; Leonid Kruglyak; Deborah A Nickerson
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

Review 4.  Detecting epistatic interactions contributing to quantitative traits.

Authors:  Robert Culverhouse; Tsvika Klein; William Shannon
Journal:  Genet Epidemiol       Date:  2004-09       Impact factor: 2.135

5.  Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.

Authors:  M R Nelson; S-A Bacanu; M Mosteller; L Li; C E Bowman; A D Roses; E H Lai; M G Ehm
Journal:  Pharmacogenomics J       Date:  2008-02-26       Impact factor: 3.550

6.  Personal genomes: The case of the missing heritability.

Authors:  Brendan Maher
Journal:  Nature       Date:  2008-11-06       Impact factor: 49.962

7.  Hereditary aspects of malignant hyperthermia.

Authors:  B A Britt; W G Locher; W Kalow
Journal:  Can Anaesth Soc J       Date:  1969-03

8.  The cellular retinoic acid binding protein I is dispensable.

Authors:  P Gorry; T Lufkin; A Dierich; C Rochette-Egly; D Décimo; P Dollé; M Mark; B Durand; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

9.  Expression of FosB during mouse development: normal development of FosB knockout mice.

Authors:  M C Gruda; J van Amsterdam; C A Rizzo; S K Durham; S Lira; R Bravo
Journal:  Oncogene       Date:  1996-05-16       Impact factor: 9.867

10.  Optimization of neural network architecture using genetic programming improves detection and modeling of gene-gene interactions in studies of human diseases.

Authors:  Marylyn D Ritchie; Bill C White; Joel S Parker; Lance W Hahn; Jason H Moore
Journal:  BMC Bioinformatics       Date:  2003-07-07       Impact factor: 3.169

View more
  5 in total

1.  Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis.

Authors:  Benjamin J Grady; Marylyn D Ritchie
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-03-01

2.  TESTING POPULATION-SPECIFIC QUANTITATIVE TRAIT ASSOCIATIONS FOR CLINICAL OUTCOME RELEVANCE IN A BIOREPOSITORY LINKED TO ELECTRONIC HEALTH RECORDS: LPA AND MYOCARDIAL INFARCTION IN AFRICAN AMERICANS.

Authors:  Logan Dumitrescu; Kirsten E Diggins; Robert Goodloe; Dana C Crawford
Journal:  Pac Symp Biocomput       Date:  2016

3.  Statistical analysis of big data on pharmacogenomics.

Authors:  Jianqing Fan; Han Liu
Journal:  Adv Drug Deliv Rev       Date:  2013-04-17       Impact factor: 15.470

4.  Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks.

Authors:  Stephen D Turner; Richard L Berg; James G Linneman; Peggy L Peissig; Dana C Crawford; Joshua C Denny; Dan M Roden; Catherine A McCarty; Marylyn D Ritchie; Russell A Wilke
Journal:  PLoS One       Date:  2011-05-11       Impact factor: 3.240

5.  Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus.

Authors:  Hector E Sanchez-Ibarra; Luisa M Reyes-Cortes; Xian-Li Jiang; Claudia M Luna-Aguirre; Dionicio Aguirre-Trevino; Ivan A Morales-Alvarado; Rafael B Leon-Cachon; Fernando Lavalle-Gonzalez; Faruck Morcos; Hugo A Barrera-Saldaña
Journal:  Front Pharmacol       Date:  2018-04-06       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.